https://orcid.org/0000-0003-0952-8621
References
- Fallahi P, Ferrari SM, Ruffilli I, et al. Advancements in the treatment of hypothyroidism with L-T4 liquid formulation or soft gel capsule: an update. Expert Opin Drug Deliv. 2017;14(5):647–655. doi:10.1080/17425247.2016.1227782
- Nagy EV, Perros P, Papini E, Katko M, Hegedus L. New formulations of levothyroxine in the treatment of hypothyroidism: trick or treat? Thyroid. 2021;31(2):193–201. doi:10.1089/thy.2020.0515
- Centanni M, Benvenga S, Sachmechi I. Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report. J Endocrinol Invest. 2017;40(12):1289–1301. doi:10.1007/s40618-017-0706-y
- Fass R, McCallum RW, Parkman HP. Treatment challenges in the management of gastroparesis-related GERD. Gastroenterol Hepatol (N Y). 2009;5(10):4–16.
- Brechmann T, Sperlbaum A, Schmiegel W. Levothyroxine therapy and impaired clearance are the strongest contributors to small intestinal bacterial overgrowth: results of a retrospective cohort study. World J Gastroenterol. 2017;23(5):842–852. doi:10.3748/wjg.v23.i5.842
- Virili C, Antonelli A, Santaguida MG, Benvenga S, Centanni M. Gastrointestinal malabsorption of thyroxine. Endocr Rev. 2019;40(1):118–136.
- Abbott RD, Sadowski A, Alt AG. Efficacy of the autoimmune protocol diet as part of a multi-disciplinary, supported lifestyle intervention for Hashimoto’s thyroiditis. Cureus. 2019;11(4):e4556.
- Burek CL, Talor MV. Environmental triggers of autoimmune thyroiditis. J Autoimmun. 2009;33(3–4):183–189. doi:10.1016/j.jaut.2009.09.001
- Clarke JO. SIBO in gastroparesis: sci-fi or science fact? Dig Dis Sci. 2014;59(3):510–512. doi:10.1007/s10620-013-3011-4
- George NS, Sankineni A, Parkman HP. Small intestinal bacterial overgrowth in gastroparesis. Dig Dis Sci. 2014;59(3):645–652. doi:10.1007/s10620-012-2426-7
- Lauritano EC, Bilotta AL, Gabrielli M, et al. Association between hypothyroidism and small intestinal bacterial overgrowth. J Clin Endocrinol Metab. 2007;92(11):4180–4184. doi:10.1210/jc.2007-0606
- Patil AD. Link between hypothyroidism and small intestinal bacterial overgrowth. Indian J Endocrinol Metab. 2014;18(3):307–309. doi:10.4103/2230-8210.131155
- Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550–1562. doi:10.1016/S0140-6736(17)30703-1
- Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm. 2009;72(1):105–110. doi:10.1016/j.ejpb.2008.10.008
- Synthroid® (levothyroxine sodium) tablets, for oral use. US prescribing information. USA: AbbVie Inc; 2018.
- McMillan M, Rotenberg KS, Vora K, et al. Comorbidities, concomitant medications, and diet as factors affecting levothyroxine therapy: results of the CONTROL surveillance project. Drugs R D. 2016;16(1):53–68. doi:10.1007/s40268-015-0116-6
- Ruchala M, Szczepanek-Parulska E, Zybek A. The influence of lactose intolerance and other gastro-intestinal tract disorders on L-thyroxine absorption. Endokrynol Pol. 2012;63(4):318–323.
- Reardon DP, Yoo PS. Levothyroxine tablet malabsorption associated with gastroparesis corrected with gelatin capsule formulation. Case Rep Endocrinol. 2016;2016:1316724.
- Virili C, Giovanella L, Fallahi P, et al. Levothyroxine therapy: changes of TSH levels by switching patients from tablet to liquid formulation. A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018;9:10. doi:10.3389/fendo.2018.00010
- Virili C, Trimboli P, Centanni M. Novel thyroxine formulations: a further step toward precision medicine. Endocrine. 2019;66(1):87–94. doi:10.1007/s12020-019-02049-x
- Tirosint®-SOL (levothyroxine sodium) oral solution. US prescribing information. Switzerland: Institut Biochimique SA (IBSA); 2000.
- Yue CS, Scarsi C, Ducharme MP. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 2012;62(12):631–636. doi:10.1055/s-0032-1329951